FDA
-
-
-
-
-
-
-
Lilly files six lawsuits over illegal sales of unapproved retatrutide
-
-
-
-
-
-
-
Oppenheimer on AtaiBeckley Inc (ATAI): 'LLY Acquisition Validates Psychedelic Advantages'
-
-
-
-
-
-
-
Lilly to present Alzheimer's disease diagnostic and therapeutic research at AAIC 2026, including new data on P-tau217 blood tests and amyloid-targeting treatment
-
-
-
-
-
-
-
Lilly's Jaypirca (pirtobrutinib) recommended by CHMP for approval in the European Union for adults with chronic lymphocytic leukemia (CLL) across all lines of therapy
-
-
-
-
-
-
-
FDA approves Lilly's EBGLYSS for eight-week dosing in atopic dermatitis
-
-
-
-
-
-
-
Lilly's triple agonist, retatrutide, drove substantial improvements in weight, A1C, knee osteoarthritis pain, and obstructive sleep apnea, demonstrating its remarkable potential to treat obesity and i
-
-
-
-
-
-
-
Lilly to present diabetes, obesity drug data at ADA conference
-
329,625 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

